{"id":923427,"date":"2026-01-04T12:03:08","date_gmt":"2026-01-04T17:03:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/final-deadline-alert-42-04-stock-drop-at-inspire-medical-systems-insp-triggers-securities-fraud-lawsuit-over-concealed-medicare-billing-software-failures-inspire-v-inventory-glut\/"},"modified":"2026-01-04T12:03:08","modified_gmt":"2026-01-04T17:03:08","slug":"final-deadline-alert-42-04-stock-drop-at-inspire-medical-systems-insp-triggers-securities-fraud-lawsuit-over-concealed-medicare-billing-software-failures-inspire-v-inventory-glut","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/final-deadline-alert-42-04-stock-drop-at-inspire-medical-systems-insp-triggers-securities-fraud-lawsuit-over-concealed-medicare-billing-software-failures-inspire-v-inventory-glut\/","title":{"rendered":"FINAL DEADLINE ALERT: $42.04 Stock Drop at Inspire Medical Systems (INSP) Triggers Securities Fraud Lawsuit Over Concealed Medicare Billing Software Failures & Inspire V Inventory Glut"},"content":{"rendered":"

\nPartner Reed Kathrein Urges Investors to Contact Firm Before January 5, 2026 Lead Plaintiff Deadline
\n<\/h2>\n
\n

SAN FRANCISCO, Jan. 04, 2026 (GLOBE NEWSWIRE) — National investor rights law firm Hagens Berman<\/strong> alerts INSP investors to the pending securities class action lawsuit against Inspire Medical Systems, Inc. (NYSE: INSP)<\/strong>. The firm is urging INSP investors who suffered substantial losses to contact its attorneys before the January 5, 2026, Lead Plaintiff Deadline<\/strong>. The lawsuit, which is currently pending in the U.S. District Court for the District of Minnesota, alleges that Inspire Medical and its executives misled investors by concealing critical operational failures surrounding the launch of its next-generation device, the Inspire V<\/strong> for obstructive sleep apnea.<\/strong><\/p>\n

\n Class Period:<\/strong> Investors who purchased Inspire Medical (INSP)<\/strong> securities between August 6, 2024, and August 4, 2025<\/strong>.<\/p>\n

\n Lead Plaintiff Deadline:<\/strong>
\n January 5, 2026<\/strong>\n <\/p>\n

\n
\n Submit Your INSP Losses Now<\/strong>
\n <\/a>: If you suffered a substantial loss on your INSP<\/strong> investment, you are encouraged to contact Hagens Berman Partner Reed Kathrein to discuss your legal rights:<\/p>\n

\n Visit: <\/strong>
\n
\n www.hbsslaw.com\/investor-fraud\/insp<\/strong>
\n <\/a>
\n Email:<\/strong>
\n
\n INSP@hbsslaw.com<\/strong>
\n <\/a>
\n Call:<\/strong>
\n 844-916-0895<\/strong>\n <\/p>\n

\n The Heart of the Inspire Medical Systems (INSP) Fraud Allegations<\/strong>\n <\/p>\n

The securities class action complaint details how Inspire Medical allegedly assured investors of its \u201coperational readiness\u201d for the Inspire V launch, claiming it was ready \u201cto throw the switch\u201d for full commercial rollout. These assurances, the lawsuit contends, concealed fundamental failures that made a successful launch impossible, leading to a catastrophic guidance cut and stock crash.<\/p>\n

The undisclosed operational issues that allegedly rendered the Company\u2019s statements materially false and misleading include:<\/p>\n\n\n\n\n\n
\n Alleged Concealment<\/strong>\n <\/td>\n\u00a0<\/td>\n\n The Truth Allegedly Revealed on Aug. 4, 2025<\/strong>\n <\/td>\n\u00a0<\/td>\n\n Impact on Business\/Stock<\/strong>\n <\/td>\n<\/tr>\n
\n Medicare & Billing Readiness<\/strong>\n <\/td>\n\u00a0<\/td>\nThe necessary software updates for Medicare claims processing<\/strong> did not take effect until July 1, 2025, meaning implanting centers could not bill for procedures, stalling early adoption.<\/td>\n\u00a0<\/td>\nDelayed Inspire V rollout and bottlenecked revenue generation.<\/td>\n<\/tr>\n
\n Excess Inventory (Channel Glut)<\/strong>\n <\/td>\n\u00a0<\/td>\nCustomers and treatment centers held a significant surplus of the older Inspire IV device<\/strong>, impacting demand for the new Inspire V product and requiring an inventory \u201cburn down.\u201d<\/td>\n\u00a0<\/td>\nThe allegedly flawed Inspire V launch led Inspire to slash its 2025 EPS guidance by over 80%.<\/strong><\/td>\n<\/tr>\n
\n Training & Onboarding<\/strong>\n <\/td>\n\u00a0<\/td>\n\u201cMany centers\u201d had not completed the essential training, contracting, and onboarding required to implant the new device.<\/td>\n\u00a0<\/td>\n\n $42.04<\/strong> per share drop and 32.4%<\/strong> decline in value.<\/td>\n<\/tr>\n<\/table>\n

\n
\n
Hagens Berman\u2019s Investigation of the Alleged Claims<\/strong>\n <\/p>\n

\u201cOur focus remains on the alleged concealment of two critical points: the Medicare claims software failure<\/strong> and the inventory glut<\/strong> of the prior Inspire IV device,\u201d said Reed Kathrein<\/strong><\/a>, <\/strong>the Hagens Berman partner leading the firm\u2019s investigation. \u201cThe suit alleges that Inspire\u2019s stock collapse was the result of management allegedly prioritizing a narrative of seamless transition over operational reality.\u201d<\/p>\n

\n What You Can Do?:<\/strong> If you purchased Inspire Medical (INSP)<\/strong> securities during the Class Period, you may have legal options. If you wish to discuss your rights or have information that may assist our investigation, please contact Hagens Berman<\/p>\n